Riskpilot← Back to searchSign inGet full accessOrfoNeuro ApS
APSActiveCVR 37768901Bjergagervej 37Manufacture of pharmaceutical preparations · NACE 2120Est. 2016— employees
Revenue 2024
DKK -199K
+35% vs 2023
EBITDA margin
100.0%
-35% vs 2023
Equity ratio
-3797.7%
Financial strength
Net profit 2024
DKK -243K
-17% vs 2023
| Revenue | DKK -199K | +35% |
| EBITDA | DKK -199K | -35% |
| Net profit | DKK -243K | -17% |
| Total assets | DKK 28K | -41% |
| Equity | DKK -1,1M | -30% |
| Employees | — | — |
Legal name
OrfoNeuro ApS
CVR number
37768901
Legal form
Anpartsselskab
NACE code
2120 · Manufacture of pharmaceutical preparations
Founded
1. juni 2016
Share capital
DKK 80.000
Employees
—
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af 1 direktør eller alle direktørerne i forening.
Company purpose
Selskabets formål er at investere i lægemidler og forestå udviklingen af sådanne, enten direkte eller indirekte og enten alene eller i samarbejde med andre samt at fungere som holdingselskab for selskaber indenfor disse områder.
Address
Bjergagervej 37
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | -10 | -7 | -204 | -146 | -155 | -79 | -90 | -148 | -199 |
| Staff expenses | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBITDA | -10 | -7 | -204 | -146 | -155 | -79 | -90 | -148 | -199 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBIT | -10 | -7 | -204 | -146 | -155 | -79 | -90 | -148 | -199 |
| Net financials | -0 | 0 | -7 | -14 | -13 | -16 | -19 | -31 | -43 |
| Profit before tax | -10 | -7 | -211 | -160 | -168 | -96 | -109 | -179 | -243 |
| Tax | -0 | -0 | -45 | -19 | -16 | -7 | -14 | 30 | -0 |
| Net profit | -10 | -7 | -166 | -140 | -153 | -88 | -95 | -208 | -243 |
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|
| Total assets | 55 | 91 | 161 | 152 | 52 | 46 | 53 | 47 | 28 |
| Equity | 50 | 43 | -123 | -263 | -416 | -504 | -599 | -808 | -1.050 |
| Long-term debt | 0 | 0 | 261 | 403 | 447 | 539 | 641 | 828 | 1.063 |
| Short-term debt | 5 | 48 | 23 | 12 | 21 | 12 | 12 | 27 | 14 |
| Total debt | 5 | 48 | 284 | 415 | 468 | 550 | 652 | 855 | 1.078 |
EBITDA margin
-19941700.0%
This company
15.8%
Market median
-126213391% vs market
20162024
Equity ratio
-3797.7%
This company
38.2%
Market median
-10042% vs market
20162024
Return on equity
-24256900.0%
This company
18.4%
Market median
-131831078% vs market
20162024
Net profit margin
-24256900.0%
This company
8.1%
Market median
-299468001% vs market
20162024
Asset turnover
-7.21×
This company
1.12×
Market median
-744% vs market
20162024
Debt / equity
1.03×
This company
0.62×
Market median
-66% vs market
20162024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via CVR / Virk · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via CVR / Virk · Period 2016-06-01 – 2016-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
JM Management | Management | 2016 | — | — |
SF Founder | Founder | 2016 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2025 | — | — | |
| Chairman | 2025 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
JIMKKS Holding ApS | Company | 66.7% | 66.7% | 2025 |
VALSTORP & COMPANY ApS | Company | 20.0% | 20.0% | 2025 |
| Individual | 5.0% | 5.0% | 2025 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
VALSTORP & COMPANY ApS
OrfoNeuro ApS Board members of OrfoNeuro ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Jens Morten Fogh | Management | 0 companies |
| Søren Fogh | Founder | 0 companies |
| Per Toft Valstorp | Board of Directors | 0 companies |
| Ulrik Spork | Chairman | 0 companies |